ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026)
ARS Pharmaceuticals' Common Equity came in at $12.51 million for Q2 2026, down 93.5% from $192.32 million a year earlier and down 79.6% from the prior quarter.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, ARS Pharmaceuticals' Common Equity was $114.26 million, down 55.5% from FY2024.
- Going back by year, Common Equity was $256.8 million in FY2024 (+11.3%), $230.76 million in FY2023 (-15.4%), $272.89 million in FY2022 and -$31.27 million in FY2021.
- The Q2 2026 figure represents the lowest quarterly Common Equity since Q3 2022.
- Year-over-year, Common Equity has declined for five consecutive quarters, with an average decline of 32.6% over the last eight quarters.
- The fastest year-over-year change in Common Equity over five years came in Q4 2024 (growth of 11.3%), and the weakest in Q2 2026 (a decline of 93.5%).
- Business Quant data shows SPRY's Common Equity at $61.31 million (Q1 2026), $114.26 million (Q4 2025) and $147.66 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | ARS Pharmaceuticals | 410.68 Mn | 266.88 Mn | 20.81 Mn | 12.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.51 Mn |
| Mar 31, 2026 | 61.31 Mn |
| Dec 31, 2025 | 114.26 Mn |
| Sep 30, 2025 | 147.66 Mn |
| Jun 30, 2025 | 192.32 Mn |
| Mar 31, 2025 | 228.97 Mn |
| Dec 31, 2024 | 256.80 Mn |
| Sep 30, 2024 | 200.98 Mn |
| Jun 30, 2024 | 215.24 Mn |
| Mar 31, 2024 | 223.87 Mn |
| Dec 31, 2023 | 230.76 Mn |
| Sep 30, 2023 | 237.28 Mn |
| Jun 30, 2023 | 248.55 Mn |
| Mar 31, 2023 | 261.16 Mn |
| Dec 31, 2022 | 272.89 Mn |
| Sep 30, 2022 | -50.16 Mn |
| Jun 30, 2022 | -44.03 Mn |
| Mar 31, 2022 | -38.26 Mn |
| Dec 31, 2021 | -31.27 Mn |
| Sep 30, 2021 | 332.13 Mn |
API Access
ARS Pharmaceuticals Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=SPRY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "SPRY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=SPRY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();